COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #102 of 264
7/28 Late treatment study
BaŞaran et al., Turk. J. Med. Sci., doi:10.3906/sag-2006-173 (Peer Reviewed)
Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU
Source   PDF   Share   Tweet
Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with HCQ+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HCQ+AZ vs. FAV, RR 0.25, p<0.001. 83% reduction for HCQ. However, there was significant confounding by indication.
There were no significant adverse events.

BaŞaran et al., 7/28/2020, prospective, Turkey, West Asia, peer-reviewed, 18 authors.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.